Objective-The glycoprotein (GP) Ib-V-IX complex regulates the adhesion, activation, and procoagulant activity of platelets.
P latelets adhere and aggregate at sites of vascular injury to form a plug, which stops blood loss. Under pathological conditions, excessive platelet accumulation after atherosclerotic plaque rupture can induce occlusive thrombus formation, leading to life-threatening ischemic complications. 1 At the elevated blood flows found in arteries, the glycoprotein (GP) Ib-V-IX receptor ensures the first step of platelet recruitment to the damaged vessel wall through its binding to von Willebrand factor (VWF) present in the subendothelium. 2 GPIb-V-IX also participates in thrombus growth by interacting with the VWF exposed at the surface of activated platelets located at the edge of the thrombus. 3 Besides, the GPIb-V-IX complex contributes to the platelet procoagulant activity, which is responsible for thrombin generation, a key factor of thrombus formation. [4] [5] [6] [7] Numerous ex vivo and in vivo studies have shown that targeting the GPIbα/VWF axis with different blockers, including antibodies, nanobodies, aptamers, or proteins isolated from snake venom, efficiently reduces thrombus growth in various experimental models. [8] [9] [10] [11] [12] [13] [14] These studies suggest that targeting the GPIb-V-IX complex could represent an interesting antithrombotic strategy. [15] [16] [17] GPIb-V-IX belongs to the leucine-rich repeat protein family and is composed of 4 type I transmembrane glycoproteins: GPIbα is disulfide linked to 2 GPIbβ subunits to form GPIb, which noncovalently associates with GPIX and GPV. [18] [19] [20] GPIbα interacts through its intracellular domain with filamin-1, which is linked to the actin cytoskeleton. This interaction plays an important role in the surface expression of the GPIb-V-IX complex and in its anchorage within the plasma membrane. [21] [22] [23] [24] GPIbα also binds to 6 members of the 14-3-3 family, which participate in integrin α IIb β 3 activation. [25] [26] [27] The intracellular domains of GPIbβ and GPV have been reported to interact with calmodulin, but the functional significance of this interaction remains to be established. All of the known extracellular ligands of the GPIb-IX complex (VWF, thrombin, Mac-1, P-selectin, thrombospondin-1, factor XI and factor XII, and high-molecular weight kininogen) bind to the 45-kDa globular N-terminal extracellular domain of GPIbα, whereas no docking site for any other molecule has been identified on GPIbβ or GPIX. The binding of VWF to GPIbα induces an intracellular signal involving a member of the Srckinase family, which activates phospholipase Cγ2 and leads to intracellular Ca 2+ mobilization and filopodia extension. 28 Studies in chinese hamster ovary (CHO) cell lines expressing mutated and deleted forms of the GPIb-IX complex have pointed to the intracellular region of GPIbβ rather than GPIbα as being critical for VWF-induced signaling. 29 However, the in vivo importance of GPIb-V-IX signaling still remains unknown.
We previously reported that the rat monoclonal antibody RAM.1 directed against the mouse GPIbβ extracellular domain inhibited VWF binding to platelets, and the adhesion of platelets and CHO cells transfected with the human GPIb-IX complex (hGPIb-IX CHO) to immobilized VWF under flow conditions. 30, 31 Although the precise mechanisms of these effects remain unclear, RAM.1 does not seem to prevent VWF binding to GPIbα through a steric hindrance notably supported by the fact that a Fab fragment of this antibody had a similar effect. 30 It has recently been reported that RAM.1 did not modify VWF binding to GPIb-IX reconstituted in phospholipid bilayer nanodiscs, further suggesting that the effect of RAM.1 may not be attributable to direct interference with the VWF-GPIbα interaction. 32 Here, we observed that RAM.1 induced a dramatic decrease in filopodia extension of hGPIb-IX CHO cells adhering to VWF, suggesting that it could also affect GPIb-mediated signals. To establish this in platelets and evaluate its impact on thrombosis, we performed in vitro and in vivo studies in mice. We observed that RAM.1 inhibited GPIb-induced filopodia extension, in vitro and ex vivo, and GPIb-mediated intracellular Ca 2+ mobilization after adhesion of mouse platelets to VWF. Interestingly, RAM.1 reduced collagen and tissue factor (TF)-induced thrombin generation in mouse platelet-rich plasma without impairing surface exposure of phosphatidylserine. RAM.1 also prevented thrombus formation in an in vitro flow system and in 2 in vivo murine thrombosis models, without affecting the tail-bleeding time. Altogether, these results suggest that targeting GPIbβ could strongly reduce GPIb-mediated signaling, thrombin generation and thrombus growth, whereas having a minor impact on hemostasis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

RAM.1 Inhibits GPIb-Mediated Signaling
The GPIb-V-IX complex supports adhesion of platelets to VWF, a process initiating an intracellular signal. Because RAM.1 was found to inhibit flow-dependent adhesion of hGPIb-IX CHO cells, we also examined its effect on GPIbmediated filopodia extension, which reflects signaling in these cells. 26 RAM.1 (10 μg/mL) did not significantly modify the number of hGPIb-IX CHO cells, adhering to VWF under static conditions ( Figure 1B ), but reduced by 73±1% the number of cells extending filopodia (n=3; P=0.001) clearly indicating impaired signaling ( Figure 1A and 1C) . Because RAM.1 is targeted against mouse GPIbβ, we next examined its effects on murine platelets. RAM.1 reduced the morphological changes of platelets with almost no cells extending ≥5 filopodia as compared with ≈42±3% in control (n=3; P=0.007), in the absence of a significant effect on adhesion ( Figure 1D-1F) . These results converge to establish that RAM.1 is an inhibitor of the GPIb-mediated signals leading to cytoskeletal reorganization. A salient feature of GPIb-mediated signals is the activation of phospholipase Cγ2, which generates inositol 1,4,5-trisphosphate through phosphatidylinositol 4,5-bisphosphate hydrolysis and ultimately leads to the mobilization of intracellular Ca 2+ stores. 28 Real-time confocal microscopy showed that RAM.1 strongly inhibited the intracellular Ca 2+ spikes of individual VWF-adherent platelets, an effect which was concomitant with the inhibition of filopodia extension ( Figure 1G-1I) . The mean increase in intracellular Ca 2+ concentration was reduced by 58±7% in the presence of RAM.1 as compared with the control (n=3; P<0.0001; Figure 1H ). Altogether these results support the view that RAM.1 efficiently inhibits GPIb-mediated signaling. This effect seems to be specific because RAM.1 did not affect platelet morphological changes, or aggregation induced by soluble agonists (adenosine 5′-disphosphate, thrombin, or the thromboxane A 2 mimetic U46619) or other immobilized proteins (collagen, fibrinogen; data not shown).
RAM.1 Reduces TF-and Collagen-Induced Thrombin Generation
The GPIb-V-IX complex is known to regulate the procoagulant activity of platelets and its defect, such as in patients with Bernard-Soulier syndrome results in a reduced prothrombin consumption. 33 In agreement with these observations, we recently reported that mouse platelets lacking GPIb have a profound defect in thrombin generation. 7 The ability of RAM.1 to decrease thrombin generation was measured in a calibrated automated thrombin assay using mouse-citrated platelet-rich plasma. RAM.1 reduced by 41±10% and 70±7%, the total amount of thrombin generated (endogenous thrombin potential) in response to TF (208±33 nmol/L versus 350±37 nmol/L thrombin×minutes; n=3; P=0.002) and collagen (173±38 nmol/L versus 568±107 nmol/L thrombin×minutes; n=3; P=0.029), respectively (Figure 2A-2C ). RAM.1 also decreased by 39±6% and 61±7%, the maximal concentration of thrombin generated (Peak) after stimulation with TF (n=3; P=0.003) or collagen (n=3; P=0.046), respectively ( Figure  2D ). As a control, we showed that Xia.B2, a function-blocking antibody binding to GPIbα, did not significantly decrease TF-induced thrombin generation in this assay ( Figure I in the online-only Data Supplement). Surprisingly, a flow cytometry analysis revealed that RAM.1 did not reduce the surface exposure of phosphatidylserine, because annexin-V binding was unchanged after stimulation with collagen-related peptide, thrombin, a mixture of collagen-related peptide and thrombin, or the Ca 2+ ionophore A23187 (n=7; P>0.05; Figure 2E ). These results indicate that RAM.1 markedly impairs thrombin generation through a mechanism that seems independent of phosphatidylserine exposure.
RAM.1 Inhibits Thrombus Formation in a Flow-Based Assay
To address the role of RAM.1 in thrombus formation in vitro, anticoagulated mouse whole blood labeled with 3,3′-dihexyloxacarbocyanine iodide was perfused over immobilized collagen. The 3D reconstructed images obtained by confocal microscopy indicated that RAM.1 (20 μg/mL) efficiently reduced the thrombus volume at a shear rate of 3000 s −1 ( Figure 3A) . Interestingly, the effect of RAM.1 was shear dependent with no inhibition at a shear rate of 300 s −1 and a progressive 28±9% (n=3; P=0.054), 47±10% (n=3; P=0.019), and 54±3% (n=3; P=0.001) reduction in the thrombus volume at 750 s −1 , 1500 s −1 , and 3000 s −1 , respectively ( Figure 3B-3E ).
RAM.1 Inhibits GPIb-Mediated Filopodia Extension Ex Vivo
To study the effects of RAM.1 in vivo, we generated F(ab)′2 fragments to prevent Fc-dependent platelet activation and subsequent removal from the circulation. We first confirmed that RAM.1 F(ab)′2 inhibited filopodia extension after adhesion of mouse platelets to VWF to a similar extent as RAM.1 immunoglobulin G ( Figure II in the online-only Data Supplement). We next verified that after intravenous injection of 1, 2, or 3 mg/kg of RAM.1 F(ab)′2, this antibody bound to circulating platelets and did not reduce the platelet count nor the expression level of GPIbα ( Figure 4A-4C) . Finally, we observed that platelets isolated 30 minutes after injection of RAM.1 F(ab)′2 fragments (3 mg/kg) exhibited a clear reduction in their ability 2+ levels. A-C, hGPIb-IX CHO cells were treated with RAM.1 (10 μg/mL) or a control antibody and allowed to adhere to immobilized VWF for 30 minutes in the presence of botrocetin (1 μg/mL) and EDTA (5 mmol/L). The cells were then fixed, stained with TRITC-phalloidin, and examined by fluorescence microscopy to obtain representative images (A). The total number of adherent cells (B) and the percentage of cells extending filopodia (ns: P>0.05; C) were determined in 8 random fields. Results represent the mean±SEM in 3 independent experiments (***P<0.001). D-F, Washed mouse platelets (3×10 7 /mL) incubated with Integrilin (40 μg/mL) were treated with RAM.1 (10 μg/mL) or a control antibody and allowed to adhere for 15 minutes to a VWF matrix in the presence of botrocetin (1 μg/mL). Adherent platelets were fixed and examined by scanning electron microscopy to obtain representative images (D). The bars indicate 10 μm. The fixed cells were also stained with TRITC-phalloidin, and the total number of adherent platelets (E) and the percentages of platelets extending 0 to 1, 2 to 4, and >5 filopodia were analyzed in 5 random fields (ns: P>0.05; F). Results represent the mean±SEM in 4 independent experiments (*P<0.05; **P<0.01). G-I, Washed mouse platelets (5×10 8 /mL) loaded with Ca 2+ indicator and morphological dyes and treated with RAM.1 (10 μg/mL) or a control antibody were allowed to adhere to immobilized human VWF in the presence of botrocetin (2 μg/mL) and Integrilin (40 μg/mL). The changes in fluorescence in individual adherent platelets were monitored by confocal microscopy and converted to Ca 2+ concentrations. G, Single-channel Oregon Green fluorescence (top) and differential interferential contrast (bottom) images depicting Ca 2+ oscillations and morphological changes of a representative platelet adhering to VWF. Scale bar, 4 μm. H, Dot plot distribution of the maximal increase in cytosolic Ca 2+ of individual platelets adhering to VWF. I, Representative Ca 2+ profile of single platelets adhering to VWF and treated or not treated with RAM.1 (***P<0.001). IgG indicates immunoglobulin G.
to extend filopodia on a VWF surface compared with untreated mice (n=5; P=0.007; Figure 4D and 4E).
RAM.1 Inhibits Thrombus Formation In Vivo
The impact of RAM.1 on thrombus formation was evaluated in 2 models of localized arterial injury. In the well-characterized model of laser injury of mesenteric arterioles, 34 20 minutes after injection of RAM.1 F(ab)′2 fragments (3 mg/kg) into C57Bl/6 mice, the thrombus area was reduced by 57±9% as compared with the control (1-5 vessels per mouse: control: n=5 [13 vessels]; RAM.1: n=5 [11 vessels]; P=0.040; Figure  5A and 5B). To confirm this result, we used a second model of arterial thrombosis in which the aorta is mechanically injured with a forceps. 35 Similarly as in the laser injury model, injection of RAM.1 F(ab)′2 fragments (3 mg/kg) strongly decreased thrombus growth (area under the curve: 48±10% reduction; control: n=9 mice; RAM.1: n=11 mice; P=0.031; Figure 5C and 5D). Overall these data indicate that targeting GPIbβ with RAM.1 inhibits thrombus growth in vivo.
RAM.1 Does Not Prolong the Tail-Bleeding Time and the Volume of Blood Loss
The effect of RAM.1 on hemostasis was investigated in a tail-bleeding assay. No prolongation of the tail-bleeding time was observed 20 minutes after injection of RAM.1 F(ab)′2 (3 mg/kg) as compared with control F(ab)′2 fragments (n=10; P>0.05; Figure 6A) . Moreover, RAM.1 did not increase the volume of blood lost over a 30-minute period of time (4.9±2.1 μL) as compared with the control (26.7±12.6 μL; n=10; P>0.05; Figure 6B ). These results suggest that treatment with RAM.1 does not modify hemostatic functions in mice.
Discussion
We originally reported that the rat antimouse GPIbβ antibody, RAM.1, decreased binding of VWF to the human GPIb-V-IX complex and impaired human platelet adhesion to VWF under flow conditions, and we wanted to further characterize the properties of this antibody especially in vivo. 30 This study extends our previous findings by providing evidence that targeting GPIbβ with RAM.1 inhibits VWF-induced GPIb signaling both in a human and in a mouse system, as shown by decreases in filopodia extension and intracellular Ca 2+ fluxes. Interestingly, RAM.1 also impacts on TF-and collagen-induced thrombin generation. Moreover, we found that RAM.1 inhibits in vitro thrombus growth after perfusion of anticoagulated mouse whole blood over collagen. This observation was in accordance with the defective thrombus formation occurring in vivo in 2 murine models based, respectively, on laser-induced injury of mesenteric arterioles and mechanical injury of the aorta. Finally, we showed that RAM.1 seems to have a minor impact on hemostasis, because it did not prolong the time to first arrest bleeding nor increased the volume of blood lost in a tail-bleeding assay.
One major finding of our previous work was the inhibition of platelet adhesion to VWF under flow conditions. 30 In the present study, we found that neither mouse platelets nor hGPIb-IX CHO cells displayed a significant decrease in adhesion to VWF in a static assay. These apparently contradictory results can probably be related to the fact that the inhibitory effect of RAM.1 on GPIbα/VWF interactions would be more evident under flow than under static conditions. One possibility is that receptor/ligand interactions being less stable under flow, they become more sensitive to an inhibitory effect. It is also possible that the use of botrocetin in the static assay, which potently increases the adhesiveness of the VWF A1 domain for GPIbα, could overcome the inhibitory effect of RAM.1.
We previously reported that binding of VWF to GPIbα activates phospholipase Cγ2 through one or more members of the Src-kinase family, leading to the mobilization of intracellular Ca 2+ stores and filopodia extension. 28 This signaling cascade was inhibited by blocking the VWF binding site of GPIbα. We now provide evidence that targeting GPIbβ with RAM.1 also inhibits GPIb signaling. This points to a role of GPIbβ in VWF-induced platelet activation, in agreement with another previous study, where we found that the intracellular region of GPIbβ, rather than that of GPIbα, participates in GPIb signaling leading to filopodia extension. 29 The mechanism is still unknown, but because its intracellular domain is devoid of catalytic activity, one may hypothesize that it acts through binding partners. So far, only 14-3-3ζ and calmodulin have been described to interact with GPIbβ. Although calmodulin has been reported to play a role in platelet shape change, its pharmacological inhibition did not affect GPIb-mediated filopodia formation after adhesion of platelets to VWF (P. Mangin and F. Lanza, unpublished data, 2003) . We and others found that the GPIbα/14-3-3ζ interaction participates in GPIb-mediated integrin α IIb β 3 activation, but not in the signaling cascade leading to filopodia extension. 25, 26 However, it was recently proposed that binding of 14-3-3ζ to the S609 residue of GPIbα regulates Src kinase and protein kinase C activation, leading to an increase in intracellular Ca 2+ concentrations. 36 Whether other as yet unidentified binding partners of GPIbβ participate in GPIb signaling remains to be determined. The mechanism through which RAM.1 inhibits GPIb signaling remains unclear. Its binding to GPIbβ could alter the organization of the GPIb-IX complex within the plasma membrane and in turn reduce the binding properties of GPIbα, which would result in the transmission of a weaker signal. 30 Alternatively, a change in conformation could disturb interaction of GPIb-IX with intracellular partners involved in GPIbmediated signaling. This hypothesis could be supported by observation that RAM.1 promotes dephosphorylation of S166 in the intracytoplasmic domain of GPIbβ, a site implicated in 14-3-3 binding. Based on reduced prothrombin consumption in patients with Bernard-Soulier syndrome, the GPIb-IX complex is known to participate in the process of thrombin generation. We provide evidence that RAM.1 inhibits thrombin generation in mouse platelet-rich plasma. Because RAM.1 did not reduce annexin-V binding in response to strong agonists, such as collagenrelated peptide, thrombin, or A23187, the mechanism involved seems to be distinct from the exposure of phosphatidylserine. Because GPIbα binds several coagulation factors, including factor XII and factor XI, high-molecular weight kininogen, and thrombin, one could hypothesize that RAM.1 reduces their binding and thereby lowers the ability of platelets to promote thrombin generation. However, we recently showed that the procoagulant function of the GPIb-V-IX complex seems to be independent of the N-terminal domain of GPIbα, which contains all known ligand-binding site. 7 Future studies are needed to precisely define the mechanism by which RAM.1 impairs thrombin generation.
We observed that RAM.1 inhibits in vitro thrombus formation during perfusion of mouse whole blood over collagen. The effect of RAM.1 was modest at low-shear rates, in agreement with the fact that other receptors, such as integrins α 2 β 1 and α IIb β 3 , participate in the initial phase of thrombus formation and can overcome blockade or absence . RAM.1 F(ab)′2 fragments injected into mice do not affect the platelet count and the expression level of glycoprotein (GP) Ibα, but inhibit GPIb-mediated filopodia extension. Control or RAM.1 F(ab)′2 fragments (1, 2, or 3 mg/kg) were injected into the jugular vein of C57Bl/6 mice. A, Washed platelets were isolated from the blood of C57Bl/6 mice injected with control or RAM.1 F(ab)′2 (1, 2, or 3 mg/kg), and bound RAM.1 was revealed with anti-F(ab)′2 antibodies. Representative histograms of RAM.1 F(ab)′2 binding to platelets determined by flow cytometry. B, The surface expression of GPIbα was determined in anticoagulated whole blood by flow cytometry. Platelets were gated by FSC/SSC characteristics (10 000 platelets per sample), and results were expressed as the geometric mean±SEM of the relative fluorescence intensity, in arbitrary units (3 mice per group). C, The platelet count was determined over time in whole blood collected into EDTA (6 mmol/L) after severing the mouse tail. D and E, Washed mouse platelets (3×10 7 /mL) from mice injected with control or RAM.1 F(ab)′2 were allowed to adhere for 15 minutes to a human von Willebrand factor (VWF) matrix in the presence of botrocetin (1 μg/mL) and Integrilin (40 μg/ mL). D, Adherent platelets were fixed, and representative images were obtained by scanning electron microscopy. The bars indicate 5 μm. E, Alternatively, the fixed platelets were stained with TRITC-phalloidin, and the numbers of platelets extending 0 to 1, 2 to 4, and >5 filopodia were analyzed in 5 random fields and expressed as the percentage of the total adherent cells (n=3). Results represent the mean±SEM in 4 independent experiments (**P<0.01). IgG indicates immunoglobulin G.
of the GPIb-V-IX complex. 37 Consistent with the key role of this receptor at high-shear rates, 2 RAM.1 had a more marked influence under these conditions. Unfortunately, the effect of RAM.1 on thrombus formation could not be evaluated in human platelets, which became activated by the antibody in whole blood. Development of a more specific agent against human GPIbβ is needed to investigate this in future studies.
Importantly, the inhibitory effect of RAM.1 was demonstrated in 2 distinct thrombosis models, suggesting that pharmacological targeting of GPIbβ could reduce thrombus growth in vivo. Because RAM.1 inhibits platelet adhesion to VWF and thrombin generation, its antithrombotic effect is likely to result from these GPIb-IX-mediated functions. Whether the effect of RAM.1 on dampening GPIb signals also participates in this process is speculative. So far, the role of GPIb signaling in thrombus growth remains elusive, and because no specific signaling molecules have been identified downstream of GPIb, evaluating its importance is challenging. We recently identified a region between R164 and P170 in the intracellular domain of GPIbβ as playing a role in GPIb signaling and are evaluating its importance in GPIbβ −/− mice transduced with human GPIbβ constructs. 29 A defect or deficiency of either GPIbα or its main ligand, VWF, leads to the hemorrhagic disorders known as Bernard-Soulier syndrome and VWF disease, respectively. 38, 39 Therefore, pharmacological targeting of the GPIbα/VWF axis might result in an increased bleeding risk. This is in agreement with the fact that the aptamer ARC1789, which blocks GPIb binding to VWF, transiently prolonged the cutaneous bleeding time in healthy volunteers and increased the bleeding risk of patients undergoing carotid endarterectomy with one of them presenting a serious adverse event of intraoperative bleeding. 40, 41 Our data indicated that RAM.1 does not prolong the mouse tail-bleeding time, suggesting no major impact on hemostasis. From these observations, we propose that targeting GPIbβ could prevent excessive thrombus growth with a potentially minor effect on the risk of bleeding.
In conclusion, this study provides evidence that a ligand of the mouse GPIbβ extracellular domain can blunt VWFinduced GPIb signaling and strongly reduce thrombin generation. This effect combined with its capacity to inhibit platelet adhesion to VWF under flow could contribute to the strong reduction in thrombus formation, suggesting that targeting the extracellular domain of GPIbβ may prevent thrombosis. 
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